Triumeq Shortage Update: What Patients Need to Know in 2026

If you've been searching for Triumeq and coming up empty, you may be wondering: is there a shortage? Here's what patients need to know as of 2026.

Is Triumeq in a Shortage? The Official Status in 2026

As of 2026, Triumeq is NOT on the FDA's official drug shortage list. The FDA's shortage database lists medications with active supply disruptions from manufacturers. ViiV Healthcare, the sole manufacturer of Triumeq, has not announced any manufacturing disruptions or supply constraints for Triumeq tablets or Triumeq PD as of this writing.

However, "not in a shortage" does not mean "easy to find at your local pharmacy." For specialty HIV medications like Triumeq, availability challenges stem from how the drug is distributed and stocked — not from manufacturing problems.

Why Patients Still Struggle to Find Triumeq

Several structural factors make Triumeq difficult to access even without a formal shortage:

Specialty medication distribution: With a retail cost of approximately $3,900–$4,600 per 30-day supply, most retail pharmacies don't proactively stock Triumeq. It must be ordered when a patient requests it.

No generic competition: There is no FDA-approved generic Triumeq as of 2026. With a single manufacturer and no generic alternatives, supply flexibility is limited.

Market shift toward Biktarvy: Biktarvy (bictegravir/emtricitabine/TAF) has become the most prescribed HIV regimen in the US. Many pharmacies prioritize stocking Biktarvy over other antiretrovirals.

Formulary restrictions: Some insurance plans require prior authorization for Triumeq, adding time and administrative burden before a prescription can be filled.

Brief History: Triumeq's Market Position

Triumeq was approved by the FDA in 2014 as one of the first fixed-dose combination tablets containing dolutegravir (an integrase strand transfer inhibitor) alongside two NRTIs, abacavir and lamivudine. It was quickly adopted as a first-line HIV regimen and by 2022 was generating approximately £1.5 billion in annual global sales for ViiV Healthcare. As newer options like Biktarvy and Dovato have entered the market, Triumeq's market share has shifted, but it remains an important treatment option for many patients.

What Should You Do If You Can't Find Triumeq?

Don't panic — and don't stop your medication. If you're running low, contact your provider immediately.

Use medfinder to quickly find pharmacies near you with Triumeq in stock.

Call ViiVConnect at 1-844-588-3288 — the manufacturer's support line can help locate pharmacies and access savings programs.

Ask your provider about specialty pharmacy options — HIV-focused specialty pharmacies reliably stock antiretrovirals and can ship directly to you.

Plan refills 7 days early to account for special orders or prior authorization delays.

What About Triumeq PD (Pediatric Formulation)?

Triumeq PD — the weight-based dispersible tablet formulation for children as young as 3 months — is also not on the FDA shortage list as of 2026. However, as a pediatric specialty HIV medication, it is even less commonly stocked at retail pharmacies than the adult tablet. Parents of children taking Triumeq PD should work closely with their child's HIV specialist and use specialty pharmacies that serve pediatric HIV patients. If you have difficulty, call ViiVConnect (1-844-588-3288) for specific help locating the pediatric formulation.

Bottom Line for 2026

Triumeq is not in a formal FDA shortage. The challenges patients face are distribution- and market-driven. The most important steps are to plan ahead, use tools like medfinder and ViiVConnect, and maintain open communication with your HIV provider. Read our complete guide on finding Triumeq in stock near you for a full action plan.